According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Phibro Animal Health Corporation has officially appointed Daniel (Dani) Bendheim as the company's Chief Executive Officer and President.

This appointment will take effect officially on July 1, 2026. This senior management change marks a significant transition in the company’s leadership. Mr. Bendheim will take on the heavy responsibility of guiding Phibro Animal Health’s future strategic direction and business operations. The company disclosed this information through SEC filings, ensuring transparency and compliance regarding key management changes. This appointment is expected to have a profound impact on the company’s long-term development trajectory.